<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T13:12:34Z</responseDate>
  <request identifier="oai:figshare.com:article/34050069" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34050069</identifier>
        <datestamp>2026-10-01T18:00:09Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_272</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_128</setSpec>
        <setSpec>category_133</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Feature coefficients in the multivariable prediction model.&lt;/p&gt;</dc:title>
          <dc:creator>Tomoaki Ueda (1780057)</dc:creator>
          <dc:creator>Kentaro Fukushima (5227799)</dc:creator>
          <dc:creator>Sunggi Chi (25157827)</dc:creator>
          <dc:creator>Hiroshi Haeno (206672)</dc:creator>
          <dc:creator>Goichi Yoshimoto (25157830)</dc:creator>
          <dc:creator>Hironori Arai (10964553)</dc:creator>
          <dc:creator>Daisuke Ikeda (425740)</dc:creator>
          <dc:creator>Motoshi Ichikawa (25157833)</dc:creator>
          <dc:creator>Naoto Takahashi (385073)</dc:creator>
          <dc:creator>Naoko Hosono (9512304)</dc:creator>
          <dc:creator>Takahiro Yamauchi (534724)</dc:creator>
          <dc:creator>Takeshi Kondo (600866)</dc:creator>
          <dc:creator>Shigeru Kusumoto (785749)</dc:creator>
          <dc:creator>Junya Kuroda (81185)</dc:creator>
          <dc:creator>Yosuke Minami (464487)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Environmental Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Hematology</dc:subject>
          <dc:subject>Plant Biology</dc:subject>
          <dc:subject>mutational patterns classified</dc:subject>
          <dc:subject>incomplete hematologic recovery</dc:subject>
          <dc:subject>improved overall survival</dc:subject>
          <dc:subject>aml ); however</dc:subject>
          <dc:subject>acute myeloid leukemia</dc:subject>
          <dc:subject>8 %, 52</dc:subject>
          <dc:subject>cri 33 %).</dc:subject>
          <dc:subject>type 1 –</dc:subject>
          <dc:subject>type 1 (&lt;</dc:subject>
          <dc:subject>type 2 framework</dc:subject>
          <dc:subject>type 2 (&lt;</dc:subject>
          <dc:subject>div &gt;&lt; p</dc:subject>
          <dc:subject>differential response patterns</dc:subject>
          <dc:subject>&gt;) groups based</dc:subject>
          <dc:subject>treatment ngs data</dc:subject>
          <dc:subject>azacitidine plus venetoclax</dc:subject>
          <dc:subject>cri following aza</dc:subject>
          <dc:subject>among 53 first</dc:subject>
          <dc:subject>type 1</dc:subject>
          <dc:subject>1 %,</dc:subject>
          <dc:subject>treatment response</dc:subject>
          <dc:subject>effective treatment</dc:subject>
          <dc:subject>≥ third</dc:subject>
          <dc:subject>world cohort</dc:subject>
          <dc:subject>tet2 &lt;/</dc:subject>
          <dc:subject>response heterogeneity</dc:subject>
          <dc:subject>patients treated</dc:subject>
          <dc:subject>nras &lt;/</dc:subject>
          <dc:subject>line settings</dc:subject>
          <dc:subject>line setting</dc:subject>
          <dc:subject>line patients</dc:subject>
          <dc:subject>generation sequencing</dc:subject>
          <dc:subject>frequently observed</dc:subject>
          <dc:subject>cytogenetic analyses</dc:subject>
          <dc:subject>complete remission</dc:subject>
          <dc:subject>clinical variables</dc:subject>
          <dc:subject>clinical determinants</dc:subject>
          <dc:subject>53 genes</dc:subject>
          <dc:description>&lt;p&gt;A. ROC curves and AUCs for two classification models (LDA and SVM) predicting response to azacitidine plus venetoclax (Aza/Ven) using baseline clinical factors in 17 evaluable cases lacking dominant type 1 or type 2 mutations. Model performance was evaluated by leave-one-out cross-validation (LOOCV). The LDA model achieved an AUC of 0.914 (95% CI, 0.744–1.000). B. Features and coefficients of the LDA model are shown. AUC, area under the curve; BM, bone marrow; CI, confidence interval; LDA, linear discriminant analysis; NCC, nuclear cell count; PB, peripheral blood; ROC, receiver operating characteristic; SVM, support vector machine; WBC, white blood cell; &lt;i&gt;WT1&lt;/i&gt;, Wilms tumor 1.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T18:00:01Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pone.0357898.g004</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Feature_coefficients_in_the_multivariable_prediction_model_p_/34050069</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
